biomarkers

New strategies for managing drug spend: RA, Cancer, Hep C
New strategies for managing drug spend: RA, Cancer, Hep CThe proliferation of specialty drugs has prompted new techniques for keeping costs in tow.
Six diseases reap benefits of biomarkers, genetic tests
Six diseases reap benefits of biomarkers, genetic testsBiomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.
Genetic testing: Two downsides to considerGenetic testing holds great promise, but there are some critical drawbacks to consider.
Top barriers to fully utilizing precision medicine biomarkersAs development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care—and discussing how to efficiently share the massive amounts of genomic data that will result.
Top 10 sessions to attend at ASH 2016This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.
Biomarkers: Top challenges and opportunities in managed careBiomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.
How biomarkers can personalize cancer immunotherapyASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
Evolving research improves lymphoma diagnosis, treatmentAs researchers uncover biomarkers for cancer subtypes, collaboration between researchers, pathologists and physicians will improve accurate diagnosis of lymphoma subtypes.
Oncology drug spending soars
Oncology drug spending soarsTotal global spending on oncology medicines – including therapeutic treatments and supportive care – reached the $100 billion threshold in 2014, while spending on oncology drugs in the U.S. increased 5.3 percent compounded annual growth rate (CAGR) in 2014 to reach $42.4 billion, according to a new report.
Researchers discover IPF biomarkers
Researchers discover IPF biomarkersIn a large, mutli-center study, researchers discovered potential biomarkers for accurately assessing idiopathic pulmonary fibrosis (IPF) disease progression. The study, published in the March 11 issue of The Lancet Respiratory Medicine, was led by R. Gisli Jenkins, PhD, with the Division of Respiratory Medicine at the University of Nottingham in the United Kingdom. The PROFILE study was funded by GlaxoSmithKline R & D and the Medical Research Council.